Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant

Saved in:
Bibliographic Details
Published in:Haematologica (Roma) Vol. 108; no. 2; pp. 615 - 620
Main Authors: Chen, George, Herr, Megan, Nowak, Jan, Ho, Christine, Almyroudis, Nikolaos, Attwood, Kristopher, Bonnewell, John, Walsh, Marissa, Segal, Brahm, Ross, Maureen, McCarthy, Philip, Hahn, Theresa
Format: Journal Article
Language:English
Published: Italy Fondazione Ferrata Storti 01.02.2023
Ferrata Storti Foundation
Subjects:
Antigens, CD19
Cytomegalovirus
Humans
Immunotherapy, Adoptive - adverse effects
Letter to the Editor
Lymphoma, B-Cell - therapy
Receptors, Antigen, T-Cell
T-Lymphocytes
ISSN:0390-6078, 1592-8721, 1592-8721
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 23
Disclosures
BS receives research funding from NextCure and Apellis and is on the advisory board for NextCure. GLC receives clinical research funding from Actinium, AlloVir, and Takeda. PLM receives consultancy fees / honoraria / research funding from Bluebird Bio, BMS/Celgene/Juno, Fate Therapeutics, Hikma, Janssen, Karyopharm, Magenta Therapeutics, Novartis, Oncopeptides, Partner Therapeutics, Sanofi, Starton Therapeutics, and Takeda. The remaining authors have no conflicts of interest to disclose.
Contributions
GLC wrote the manuscript. GLC and MH designed research. GLC, MH, JN, NA, NW.JB,CH, MR,BS, PLM, and TH provided data. GLC, MH, BS, PLM, and TH analyzed data. All authors read and commented on the manuscript.
Please address requests for data to GC.
Data-sharing statement
ISSN:0390-6078
1592-8721
1592-8721
DOI:10.3324/haematol.2022.281719